Lynn Mara Schuchter, M.D.
Madlyn and Leonard Abramson Professor of Clinical Oncology
Attending Physician, Hospital of the University of Pennsylvania
Internal Advisory Board Member, University of Pennsylvania Center for Health Incentives and Behavioral Economics
Internal Advisory Board Member , Palliative and Advanced Illness Research Center (PAIR)
Director, Tara Miller Melanoma Center, Abramson Cancer Center
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
3rd Floor, South Pavilion
Office #3-300
3400 Civic Center Blvd
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
3rd Floor, South Pavilion
Office #3-300
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-662-3011
Education:
B.S.
University of Michigan, 1978.
M.D.
Chicago Medical School, 1982.
Permanent linkB.S.
University of Michigan, 1978.
M.D.
Chicago Medical School, 1982.
Selected Publications
Shafique N, Farooq MS, Mattfeld V, Vargas GM, Xu X, Schuchter L, Amaravadi R, Mitchell T, Miura J, Karakousis G.: ASO Visual Abstract: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma. Ann Surg Oncol. December 2025.Shafique N, Farooq MS, Mattfeld V, Vargas GM, Xu X, Schuchter L, Amaravadi R, Mitchell T, Miura JT, Karakousis GC: Single-Dose Neoadjuvant Pembrolizumab in Resectable Metastatic Melanoma. Ann Surg Oncol. September 2025.
Bange EM, Coughlin KQ, Li W, Brown TJ, Ragusano D, Balar E, Arasappan D, Nnaji M, Kim E, Alban C, Uppuluri S, Moriarty E, Bange T, Zinck L, Smith D, Josephs M, Harrigan JJ, Cohen RB, Zubka D, Rosin R, Balachandran M, Long Q, Bilger A, Schuchter LM, Mamtani M, Shulman LN, Guerra CE, Mamtani R: A Text Message Intervention to Minimize the Time Burden of Cancer Care. NEJM Catal Innov Care Deliv February 2025.
Guo Y, Wang H, Liu S, Zhang X, Zhu X, Huang L, Zhong W, Guan L, Chen Y, Xiao M, Ou L, Yang J, Chen X, Huang AC, Mitchell T, Amaravadi R, Karakousis G, Miura J, Schuchter L, Flowers A, Zheng Q, Mou H, Gimotty P, Herlyn M, Guo W, Xu X.: Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells. Sci Adv. January 2025.
Sargen MR, Barnhill RL, Elder DE, Swetter SM, Prieto VG, Ko JS, Bahrami A, Gerami P, Karunamurthy A, Pappo AS, Schuchter LM, LeBoit PE, Yeh I, Kirkwood JM, Jen M, Dunkel IJ, Durham MM, Christison-Lagay ER, Austin MT, Aldrink JH, Mehrhoff C, Hawryluk EB, Chu EY, Busam KJ, Sondak V, Messina J, Puig S, Colebatch AJ, Coughlin CC, Berrebi KG, Laetsch TW, Mitchell SG, Seynnaeve B.J : Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. Clin Oncol. October 2024.
Ma KL, Mitchell TC, Dougher M, Sharon CE, Tortorello GN, Elder DE, Morgan EE, Gimotty PA, Huang AC, Amaravadi RK, Schuchter LM, Flowers A, Miura JT, Karakousis GC, Xu X.: Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathological response and recurrence-free survival. Clin Cancer Res September 2024.
Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TC, Farwell MD, Herati RS, Huang AC: Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. Cancer Cell August 2024.
Sharon CE, Tortorello GN, Ma KL, Huang AC, Xu X, Giles LR, McGettigan S, Kreider K, Schuchter LM, Mathew AJ, Amaravadi RK, Gimotty PA, Miura JT, Karakousis GC, Mitchell TC: Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812] Ann Oncol August 2024.
Takvorian SU, Gabriel P, Wileyto EP, Blumenthal D, Tejada S, Clifton ABW, Asch DA, Buttenheim AM, Rendle KA, Shelton RC, Chaiyachati KH, Fayanju OM, Ware S, Schuchter LM, Kumar P, Salam T, Lieberman A, Ragusano D, Bauer AM, Scott CA, Shulman LN, Schnoll R, Beidas RS, Bekelman JE, Parikh RB: Clinician- and Patient-Directed Communication Strategies for Patients With Cancer at High Mortality Risk: A Cluster Randomized Trial. JAMA Network Open July 2024.
Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, Mick R, Schubert E, McGettigan S, Kreider K, Xu W, Wherry EJ, Schuchter LM, Amaravadi RK, Mitchell TC, Farwell MD: FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma. Clin Cancer Res May 2024.